Contrast-Enhanced Ultrasound in Diagnosing Patients With Liver Cancer Undergoing Yttrium-90 Radioembolization

Withdrawn before enrolling · Not applicable

Conditions studied: Hepatocellular Carcinoma

In brief

This pilot clinical trial studies how well contrast-enhanced ultrasound in diagnosing patients with liver cancer who are undergoing Yttrium-90 radioembolization. Contrast-enhanced ultrasound may provide detailed imaging of the tumor arteries after the injection of a contrast-agent consisting of microbubbles, and may predict how much Yttrium-90 will deposit in the tumor.

Key facts

Study ID

NCT03300401

Run by

University of Southern California

People needed

0

Starts

2017-11-07

Expected to finish

2020-11-07

Last updated by the study team

2019-05-16

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients scheduled for 90Y radioembolization for HCC as part of their standard of care

You may not qualify if…

• Patients who have already received tumor treatment (either systemic or loco-regional such as previous Y90RE, microwave or radiofrequency [RF] ablation or transarterial chemoembolization [TACE])
• Pregnant or nursing
• Known cardiac shunt
• Known pulmonary hypertension
• History of hypersensitivity to Definity (perflutren lipid microsphere) or Lumason
• History of hypersensitivity to iodinated contrast agent
• Cannot consent for himself or herself

Where it is running

• USC/Norris Comprehensive Cancer Center — Los Angeles, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.